COVID‑19 drug development is the research process to develop a preventative vaccine or therapeutic prescription drug that would alleviate the severity of 2019-20 coronavirus disease (COVID‑19). Internationally during April 2020, some 250 drug companies, biotechnology firms, university research groups, and health organizations were developing 115 vaccine candidates and 153 potential therapies for COVID‑19 disease in various stages of preclinical or clinical research.
The Coalition for Epidemic Preparedness Innovations (CEPI) is working with global health authorities and vaccine developers to support the development of vaccines against COVID-19. To facilitate this effort, we have developed and are continuously maintaining an overview of the global landscape of COVID-19 vaccine development activity. Our landscape database includes vaccine development programmes reported through the WHO’s authoritative and continually updated list, along with other projects identified from publicly available and proprietary sources.